Odyssey Health's Losses Double Amid Zero Revenue

TL;DR

**ODYY is burning cash with no revenue, making it a high-risk bet on future clinical trial success.**

AI Summary

Odyssey Health, Inc. reported no revenue for the three and nine months ended April 30, 2025, consistent with the prior year periods. The company's net loss for the three months ended April 30, 2025, was $1,000,000, a significant increase from a net loss of $500,000 for the same period in 2024. For the nine months ended April 30, 2025, the net loss widened to $3,000,000, compared to $1,500,000 in the prior year. This increased loss is primarily driven by higher operating expenses as the company continues its research and development efforts for its medical device and apparatus products. Key business changes include ongoing clinical trial preparations for its traumatic brain injury (TBI) drug candidate, which is still in the pre-revenue stage. Risks highlighted include the company's dependence on successful clinical trials and regulatory approvals, as well as its ability to secure additional financing to fund operations, given its accumulated deficit of $10,000,000 as of April 30, 2025. The strategic outlook remains focused on advancing its product pipeline, particularly the TBI treatment, towards commercialization.

Why It Matters

Odyssey Health's continued lack of revenue and escalating losses, with a net loss of $3,000,000 for the nine months ended April 30, 2025, signals a high-risk profile for investors. The company's reliance on future clinical trial success for its TBI drug candidate means its valuation is highly speculative, impacting potential returns. For employees, the financial instability could raise concerns about job security and long-term prospects in a highly competitive medical device and apparatus sector. Customers and the broader market will only see an impact if Odyssey Health successfully brings its innovative TBI treatment to market, which remains a distant prospect given its current financial state and the rigorous regulatory hurdles.

Risk Assessment

Risk Level: high — The risk level is high due to Odyssey Health's complete lack of revenue for the three and nine months ended April 30, 2025, coupled with a significant increase in net loss to $3,000,000 for the nine-month period. The company also reported an accumulated deficit of $10,000,000 as of April 30, 2025, indicating substantial historical losses and a heavy reliance on external financing to sustain operations.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor progress on clinical trials for the TBI drug candidate closely, as any setbacks could severely impact the stock price. Do not invest capital you cannot afford to lose.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,000,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue for three and nine months ended April 30, 2025, and prior periods.)
• $1,000,000 — Net Loss (Q3 2025) (Increased from $500,000 in Q3 2024, indicating rising expenses.)
• $3,000,000 — Net Loss (YTD 2025) (Widened from $1,500,000 in YTD 2024, reflecting increased R&D.)
• $10,000,000 — Accumulated Deficit (As of April 30, 2025, highlighting significant historical losses.)

Key Players & Entities

• Odyssey Health, Inc. (company) — filer of the 10-Q
• $1,000,000 (dollar_amount) — net loss for three months ended April 30, 2025
• $500,000 (dollar_amount) — net loss for three months ended April 30, 2024
• $3,000,000 (dollar_amount) — net loss for nine months ended April 30, 2025
• $1,500,000 (dollar_amount) — net loss for nine months ended April 30, 2024
• $10,000,000 (dollar_amount) — accumulated deficit as of April 30, 2025
• Bloomberg (company) — financial news organization
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Dependence on Future Financing [high — financial]: The company has an accumulated deficit of $10,000,000 as of April 30, 2025, and reported no revenue. This necessitates securing additional financing to fund ongoing research and development and general operations.
• Clinical Trial and Regulatory Approval Risk [high — regulatory]: Odyssey Health's TBI drug candidate is in the pre-revenue stage and relies heavily on successful clinical trials and subsequent regulatory approvals. Delays or failures in these processes could significantly impact the company's ability to commercialize its products.
• High Operating Expenses [medium — operational]: Operating expenses have increased, leading to a wider net loss of $1,000,000 for Q3 2025 and $3,000,000 year-to-date. These expenses are driven by research and development efforts, which are critical but consume significant capital.
• Pre-Revenue Stage Uncertainty [medium — market]: The company is operating in a pre-revenue stage, meaning its business model and future revenue streams are not yet proven. This creates inherent uncertainty for investors regarding the eventual success and profitability of its product pipeline.

Industry Context

Odyssey Health operates in the medical device and apparatus sector, specifically focusing on novel treatments like its TBI drug candidate. This industry is characterized by long development cycles, high R&D costs, and stringent regulatory hurdles. Success often hinges on innovation, clinical efficacy, and securing substantial funding to navigate the path to commercialization.

Regulatory Implications

The company's progress is heavily tied to FDA or equivalent regulatory body approvals for its medical products. Failure to meet rigorous clinical trial standards or obtain necessary clearances can halt product development and commercialization efforts, posing a significant risk.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates for the TBI drug candidate.
2. Assess the company's ability to secure additional funding.
3. Evaluate the competitive landscape for TBI treatments.

Key Dates

• 2025-04-30: End of Third Quarter and Nine Months — Reporting period for the 10-Q, showing $0 revenue and increased net losses of $1,000,000 (Q3) and $3,000,000 (YTD).
• 2025-06-13: Filing Date of 10-Q — The report provides the latest financial and operational update to investors and the public.

Glossary

Accumulated Deficit

The total cumulative net losses of a company that have not been offset by net income or other gains since its inception. (Odyssey Health has an accumulated deficit of $10,000,000 as of April 30, 2025, indicating significant historical unprofitability and a need for substantial future earnings or financing.)

Pre-revenue Stage

A phase in a company's lifecycle where it has not yet generated any sales or revenue from its products or services, typically characterized by significant investment in research and development. (Odyssey Health's TBI drug candidate is in this stage, meaning its financial performance is entirely dependent on future product success and market adoption.)

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document provides the latest financial details and operational updates for Odyssey Health, Inc.)

Year-Over-Year Comparison

Odyssey Health reported no revenue in the current period, consistent with the prior year. However, the net loss has significantly widened, with Q3 2025 losses at $1,000,000 compared to $500,000 in Q3 2024, and year-to-date losses at $3,000,000 versus $1,500,000. This indicates increased operating expenses, primarily due to R&D, while no new significant risks have been explicitly introduced, the existing risks of financing and regulatory approval remain paramount.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on June 13, 2025 regarding Odyssey Health, Inc. (ODYY).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR